Clinical Trial Update: Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a subcutaneous four-month sustained-release formulation of triptorelin in prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Triptorelin (triptorelin)

Snippet

Sponsor: Ipsen | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED